Pharmaceutical Executive April 13, 2021
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
While the world remains laser-focused on COVID-19, the development of powerful vaccines in record time, and enough political, societal, and economic uncertainty to rattle the nerves of investors, the Wall Street community mostly has kept its collective attention on life after the pandemic.
In other words, it turned out to be a pretty good run for the financial markets and for investors in general, employing new and creative strategies to take full advantage of the next opportunity around the corner.
For many in biopharma, that next opportunity came in the form of...
Today's Sponsors
Today's Sponsor